This phase I trial studies how well lorcaserin works in treating chemotherapy-induced peripheral neuropathy in patients with stage I-IV gastrointestinal or breast cancer. Chemotherapy-induced peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. This condition can occur in patients who have received taxane chemotherapy drugs, or the chemotherapy drug oxaliplatin. Lorcaserin may improve chemotherapy-induced peripheral neuropathy by reducing pain, preventing or relieving joint symptoms, and improving balance.

开始日期2020-11-01

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

NCT04572243

/ Terminated临床3期

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.

开始日期2020-09-23

申办/合作机构

Eisai, Inc.

NCT04396834

/ Terminated临床2期IIT

Behavioral Mechanisms of Lorcaserin Treatment for Smoking Cessation

Identifying new medication options is critical for curbing the health burdens of cigarette smoking. Currently approved smoking cessation medications act on nicotinic receptors, and additional work is needed to identify medications with alternate pharmacological targets. Based on evidence that the serotonin system plays a role in nicotine consumption and relapse, this study will examine whether a selective serotonin medication alters smoking-related behaviors and responses to cigarette smoking under controlled conditions, informing its potential utility for smoking cessation.

开始日期2019-12-04

申办/合作机构

The Mind Research Network

100 项与盐酸绿卡色林相关的临床结果

登录后查看更多信息

100 项与盐酸绿卡色林相关的转化医学

登录后查看更多信息

100 项与盐酸绿卡色林相关的专利（医药）

登录后查看更多信息

584

项与盐酸绿卡色林相关的文献（医药）

2025-10-01·PHYSIOLOGY & BEHAVIOR

Eating a high fat diet enhances sensitivity of rats to serotonin receptor agonists

Article

作者: Serafine, Katherine M ; Landavazo, Antonio ; Blough, Bruce E ; Beltran, Nina M ; Ramos, Jeremiah

RATIONALE:

Serotonergic medications are used for treating anxiety, depression, and obesity. Serotonin (5-HT) receptor agonists (e.g., 8-OH-DPAT, lorcaserin, and WAY 163909) induce unconditioned effects in rodents (e.g., lower lip retraction, flat body posture, penile erections, and forepaw treading), which can be used to measure drug sensitivity.

OBJECTIVE:

The unconditioned effects of serotonergic drugs are hypothesized to be enhanced by eating a high fat diet.

METHODS:

Male (n = 32) and female (n = 16) Sprague-Dawley rats eating high fat (60 % kcal from fat) or standard (17 % kcal from fat) laboratory chow were tested once weekly with cumulative doses of 5-HT receptor agonists (8-OH-DPAT [0.01-1.0 mg/kg, (subcutaneously, s.c.)], lorcaserin [1.0-32.0 mg/kg, (intraperitoneally, i.p.)], or WAY 163909 [1.0-32.0 mg/kg, i.p.] alone and in combination with antagonists selective for 5-HT_1A (WAY 100635; 0.178 mg/kg, s.c.), or 5-HT_2C (SB 242084; 1.0 mg/kg; i.p.) receptors.

RESULTS:

8-OH-DPAT induced lower lip retraction, flat body posture, and forepaw treading, while WAY 163909 and lorcaserin induced forepaw treading, penile erections, and weight loss. Rats eating high fat chow were more sensitive to 8-OH-DPAT-induced lower lip retraction and forepaw treading induced by 8-OH-DPAT, lorcaserin, and WAY 163909 as compared to rats eating standard chow. Lorcaserin and WAY 163909-induced penile erections were not different between rats eating high fat or standard chow. Forepaw treading, lower lip retraction, and flat body posture were attenuated by WAY 100635. In contrast, penile erections were attenuated by SB 242084.

CONCLUSIONS:

These results suggest that nutritional factors impact drug sensitivity in ways that might be relevant for the therapeutic effectiveness and side effect severity of serotonergic drugs.

2025-08-01·BEHAVIOURAL PHARMACOLOGY

Role of serotonin 5HT2C receptors in the discriminative stimulus properties of lorcaserin in male C57BL/6 mice

Article

作者: Shelton, Keith L. ; Porter, Joseph H. ; Hillhouse, Todd M. ; Nicholson, Katherine L. ; Zhang, Fan ; Meltzer, Herbert Y.

The serotonin 2C receptor (5-HT2C) has been investigated as a potential therapeutic target for a variety of psychiatric disorders, as well as the treatment of obesity. A stumbling block in the development of these medications is identifying agonists with selectivity for 5-HT2C over 5-HT2A and 5-HT2B. Lorcaserin (Belviq) is a serotonin 5-HT2C agonist that was previously marketed as a weight-loss medication but was voluntarily withdrawn from the market because of a small, but an increased risk of serious side effects. The present study examined the discriminative stimulus properties of 2.0 mg/kg lorcaserin in a two-lever drug discrimination assay in male C57BL/6 mice using a fixed ratio 12 reinforcement schedule. A generalization curve with lorcaserin yielded an effective dose50 (ED50) = 0.56 mg/kg for substitution for the training dose. Lorcaserin produced a rapid onset, but short-acting (~60 min), discriminative stimulus, as full generalization was found as early as 15 min after drug administration. The 5-HT2C agonist meta-chlorophenylpiperazine fully substituted for lorcaserin with an ED50 = 0.31 mg/kg, and the 5-HT2C antagonist SB 242084 significantly blocked lorcaserin-lever responding (maximal effect at 0.25 mg/kg dose). Conversely, the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin did not substitute for lorcaserin. Thus, lorcaserin’s discriminative stimulus appears to be mediated by agonist activity at 5HT2C receptors in C57BL/6 mice. These results demonstrated that lorcaserin drug discrimination can be trained in C57BL/6 mice and that it is a useful in-vivo assay for the future development of psychotherapeutic drugs for psychiatric disorders with selective 5-HT2C agonist activity.

2025-07-11·Science Advances

G proteins of the G ₁₂ family expressed by POMC neurons regulate key metabolic functions

Article

作者: Inoue, Asuka ; Pittala, Srinivas ; Lu, Huiyan ; Hwang, Eunsang ; Cui, Yinghong ; Williams, Kevin W. ; Haspula, Dhanush ; Wess, Jürgen ; Ajwani, Jason ; Gavrilova, Oksana ; Portillo, Bryan ; Xiong, Yan ; Jin, Jian ; Cui, Zhenzhong

Proopiomelanocortin (POMC) neurons play a key role in maintaining glucose and energy homeostasis. POMC neurons express many heterotrimeric guanine nucleotide–binding protein (G protein)–coupled receptors that are linked to different functional classes of G proteins. The potential role of G 12/13 in regulating the function of central POMC neurons remains unknown. To address this question, we used a chemogenetic approach to selectively stimulate G 12/13 signaling in POMC neurons. We found that receptor-mediated activation of G 12/13 signaling in POMC neurons caused notable improvements in glucose homeostasis in lean and obese mice. Stimulation of G 12/13 signaling in POMC neurons also enhanced the physiological actions of leptin. Studies with G 12/13 knockout mice showed that G 12/13 signaling in POMC neurons mediated the beneficial metabolic effects of lorcaserin, an appetite-suppressant drug that selectively activates serotonin 5-HT 2C receptors. These findings indicate that G 12/13 -coupled receptors expressed by POMC neurons represent potential targets for advanced classes of antidiabetic and appetite-suppressant drugs.

项与盐酸绿卡色林相关的新闻（医药）

2025-07-09

·GlobeNewswire-Health Care

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors. Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nutrition, and diagnostics. His expertise spans from preclinical translational medicine through Phase 1-4 clinical development. Notably, his leadership has contributed to multiple drug development programs, including two successful regulatory approvals (NDA/sBLA): infliximab for pediatric Crohn’s disease and lorcaserin for morbid obesity. Following a successful academic career as an Assistant Professor at both Duke University and the University of Pennsylvania, Dr. Chuang transitioned into the pharmaceutical industry, where he has earned a reputation for simplifying complex challenges into actionable development strategies. His work includes significant contributions to programs targeting inflammatory bowel diseases (IBD), including infliximab and vedolizumab. “We are very pleased to welcome Emil to our Board of Directors. His extensive clinical development experience and deep understanding of IBD will provide valuable insight as we continue to execute our clinical programs. We look forward to leveraging his knowledge to advance our pipeline,” commented JD Finley, Chief Executive Officer of Palisade Bio. “I am excited to work with the Palisade team to help unlock the full value of its pipeline and bring meaningful solutions to patients where there remain unmet medical needs,” added Dr. Chuang. “The progress made to date, as well as the data demonstrated by PALI-2108 for addressing Fibrostenotic Crohn’s Disease and Ulcerative Colitis is very compelling, and I look forward to helping advance these important programs.” Dr. Chuang currently serves as the Chief Medical Officer at Intrinsic Medicine, a privately held biotechnology company. He also leads Chuang Global Consulting, his independent advisory firm. His prior leadership roles include Head of GI Clinical Development for Nestlé Health Science, Head of GI Translational Research and Early Clinical at Takeda, and Head of GI Precision Medicine at Progenity. Over the course of his career, Dr. Chuang has authored more than 80 peer-reviewed publications, abstracts, and book chapters. He received his medical degree (MB BS) from the University of Sydney, Australia and completed his pediatrics specialty training (FRACP) in Australia before moving to the United States, where he completed subspecialty training in both pediatric gastroenterology and nutrition. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study and indications and anticipated benefits of PALI-2108. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the timing and success of preclinical studies and clinical trials conducted by the Company; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; the Company’s need to raise significant additional funds to continue its plans and operations; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas908-824-0775PALI@jtcir.com Attachment Figure: 1

高管变更上市批准

2025-05-21

·国际糖尿病idiabetes

从减重到心血管保护的循证实践——基于司美格鲁肽多项国际研究的深度解析

点击“蓝字”关注我们编者按：肥胖是全球面临的重大公共卫生问题，预计到2035年，全球超半数人口将超重或肥胖。肥胖不仅直接导致胰岛素抵抗、高血压等代谢异常，更与心血管疾病（CVD）风险密切相关——2015年全球400万例死亡归因于肥胖，其中超三分之二与心血管事件相关。尽管生活方式干预是基石，但长期依从性低、效果有限，而传统减重药物因心血管安全性问题（如芬特明-托吡酯、氯卡色林）陆续退市，临床亟需兼具减重与心血管保护的新型药物。司美格鲁肽作为长效GLP-1受体激动剂，在多项大型随机对照试验中展现出“双重优势”：不仅显著降低体重，更通过改善内皮功能、抗炎、调节代谢等机制，为肥胖合并CVD患者带来明确心血管获益。本文邀请浙江省人民医院武晓泓教授结合SELECT、STEP HFpEF、STEP-HFpEF-DM及STEP系列研究，解析其在不同人群中的循证证据。武晓泓主任医师、教授浙江省人民医院浙江省人民医院内分泌科主任浙江省糖尿病防治中心副主任浙江省万人计划科技创新领军人才、卫生创新人才中华预防医学会甲状腺疾病防治专业委员会常务委员中国临床肿瘤学会甲状腺癌专家委员会副主任委员中国微循环学会糖尿病与微循环专业委员会常委兼秘书长中国医师协会内分泌代谢科医师分会委员浙江省预防医学会糖尿病预防与控制专业委员会主任委员浙江省医学会内分泌学分会副主任委员浙江省医师协会内分泌代谢科医师分会副会长主持国家自然科学基金4项、部省级项目12项，发表论文117篇获得省市级科研奖励5次、荣获市五一劳动奖章司美格鲁肽研究矩阵：覆盖多元人群的心血管保护证据司美格鲁肽的心血管获益证据来自三大研究方向（图1）： 1. CVD二级预防（SELECT研究）：针对已有CVD的非糖尿病肥胖人群，评估硬终点（心血管死亡、心梗、卒中）。 2. 心衰特定人群（STEP HFpEF、STEP-HFpEF-DM研究）：聚焦射血分数保留型心衰（HFpEF）合并肥胖或糖尿病患者，关注症状、运动耐量及生物标志物。 3. 广泛肥胖人群（STEP系列）：覆盖非糖尿病、合并2型糖尿病（T2DM）、东亚人群等，评估减重与心血管风险因素的综合改善。图1. 司美格鲁肽2.4mg 临床试验项目概览SELECT研究：首个证实减重药物心血管硬终点获益的里程碑试验SELECT研究[1]纳入17,604例45岁以上、BMI≥27kg/m2且合并CVD（心梗、卒中或外周动脉疾病）的非糖尿病患者，随机接受司美格鲁肽2.4mg或安慰剂，随访39.8个月。主要终点结果显示司美格鲁肽组主要心血管事件（心血管死亡、非致死性心梗、非致死性卒中）风险降低20%（HR 0.80, 95%CI:0.72~0.90, P<0.001）（图2），且在不同亚组和不同心血管结局中显示了一致的获益，并有效降低了体重且可长期维持、最长达4年以上，同时改善了心血管危险因素。安全性方面，司美格鲁肽组SAE发生率显著低于安慰剂组（33.4% vs 36.4%，P<0.001），长期安全性和耐受性良好。图2. 主要心血管复合终点（心血管死亡、非致死性心肌梗死或非致死性卒中）的累积发生率：与安慰剂相比，司美格鲁肽2.4mg显著降低MACE风险达20%作为首个证实非糖尿病肥胖患者通过减重药物降低心血管硬终点的研究，SELECT研究打破了“减重药物仅改善代谢指标”的局限，具有里程碑意义。其结果支持司美格鲁肽用于CVD二级预防，尤其适用于合并肥胖的冠心病、卒中病史患者。 STEP HFpEF与STEP-HFpEF-DM：破解肥胖型心衰的治疗困境在射血分数保留型心衰（HFpEF）这一治疗难点领域，STEP HFpEF 研究[2]设定双重主要终点为从基线至第52周时堪萨斯城心肌病问卷评分（KCCQ-CSS）的变化，以及体重的百分比变化。研究纳入 529 例 BMI≥30 kg/m2的患者，发现司美格鲁肽治疗 52 周后，KCCQ-CSS较安慰剂组显著提高 7.8 分（16.6 vs. 8.7, P<0.001）（图3.A），体重降幅达 13.3% （图3.B） 6 分钟步行距离增加 20.3 米（21.5 vs. 1.2, P<0.001），NT-proBNP 水平降低 20.9%。值得注意的是，尽管司美格鲁肽组体重显著降低，但 NT-proBNP 的显著下降与体重变化的相关性较弱，提示其可能通过改善心肌舒张功能、降低心室充盈压等机制直接改善心衰病理生理。本研究也证实在合并肥胖的HFpEF患者中，每周一次剂量为2.4 mg的司美格鲁肽治疗，相较于安慰剂可更大程度地减轻与心力衰竭相关的症状和体力受限，更明显地改善运动功能，并实现更显著的体重减轻。图3. 双重主要终点从基线到第 52 周的变化针对合并T2DM的HFpEF患者，STEP-HFpEF-DM 研究[3]进一步证实，司美格鲁肽在减重（9.8% vs. 3.4%）的同时（图4.A），使 KCCQ-CSS 评分提高 7.3 分（图4.B），6 分钟步行距离增加 14.3 米，HbA1c降低 0.7%，且不增加低血糖风险。图4. 双重主要终点从基线到第 52 周的变化HFpEF占心衰患者的50%以上，传统治疗手段有限。这两项研究打破了 “肥胖悖论” 的局限，表明司美格鲁肽对肥胖相关心衰的症状缓解和生物标志物改善具有普适性，为“肥胖-HFpEF-糖尿病”共病提供新策略。 STEP系列研究：全人群覆盖的减重与心血管风险因素优化从非糖尿病肥胖到合并T2DM（2型糖尿病）患者，从欧美人群到东亚亚组，STEP系列研究全面验证了司美格鲁肽的疗效。在针对成人超重或肥胖（无糖尿病）的STEP 1研究[4]中，68周治疗后，司美格鲁肽组平均体重下降14.9%，远超安慰剂组的2.4% ，86.4%的参与者实现至少5%的体重降低（安慰剂组仅31.5%）。同时，该组多项心血管风险指标明显改善，腰围减少13.54 cm，收缩压降低6.16 mmHg，舒张压降低2.83 mmHg，总胆固醇、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、游离脂肪酸和甘油三酯水平下降，C反应蛋白降低53%，事后分析[5]还显示其可显著降低10年ASCVD风险评分（图5）。图5. STEP 1事后分析显示司美格鲁肽2.4mg减少10年ASCVD中高危人群的比例STEP 2研究[6]聚焦成人超重或肥胖合并2型糖尿病患者，结果显示，第68周时司美格鲁肽2.4mg组平均体重下降9.6%（安慰剂组3.4%），68.8%的患者减重至少5%（安慰剂组28.5%）。在血糖控制方面，HbA1c降低1.6%（安慰剂组0.4%），空腹血糖降低2.1mmol/L（安慰剂组0.1mmol/L）；血压方面，收缩压降低3.9mmHg（安慰剂组0.5mmHg）；血脂改善明显，甘油三酯第68周与基线比值为0.78，且C反应蛋白和尿白蛋白与肌酐比值降低。针对成人超重或肥胖（无糖尿病）人群的STEP 3研究[7]中，68周治疗后，司美格鲁肽组平均体重下降16.0% ，远超安慰剂组的5.7%，更多患者实现至少5%、10%、15%的体重下降，比例分别为86.6%、75.3%、55.8%，而安慰剂组仅为47.6%、27.0%、13.2%。同时，司美格鲁肽组在多项心血管风险指标上改善明显，腰围减少14.6cm，收缩压降低5.6mmHg，舒张压降低3.0mmHg，总胆固醇、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、游离脂肪酸和甘油三酯水平下降，C反应蛋白降低59.6%。在STEP 6研究[8]中，司美格鲁肽注射液组患者平均体重减轻13.2%，而安慰剂组平均减重2.1%。与此同时，司美格鲁肽注射液组患者的收缩压降低了约11mmHg，C反应蛋白（CRP）水平降低了58%，纤溶酶原激活物抑制剂1（PAI-1）水平降低了32%。此外，STEP 7研究[9]也证实了司美格鲁肽注射液对糖代谢的积极影响。研究发现，司美格鲁肽注射液组患者的糖化血红蛋白（HbA1c）降低了0.8%，总胆固醇降低了5.2%，甘油三酯降低了28%。也证实了司美格鲁肽注射液对糖代谢的积极影响。研究发现，司美格鲁肽注射液组患者的糖化血红蛋白（HbA1c）降低了0.8%，总胆固醇降低了5.2%，甘油三酯降低了28%。综合这些研究结果可见，司美格鲁肽在不同种族的肥胖人群中，无论是否合并 2 型糖尿病，均展现出良好的疗效。它不仅能够显著减轻体重，还能从多个方面改善心血管风险指标，有效降低心血管疾病的风险，为心血管健康带来积极且全面的影响。STEP 1,3,4事后分析：长期治疗的持续保护效应司美格鲁肽在改善心血管风险因素方面成效显著。在STEP 1、3、4研究事后分析[10]中，针对成人超重或肥胖且伴有前驱糖尿病的患者，使用司美格鲁肽展现出多方面的心血管获益。治疗68周后，司美格鲁肽组在多项指标上优于安慰剂组，血糖代谢显著改善，糖尿病前期患者血糖恢复正常的比例更高（STEP 1中84.1% vs 47.8%；STEP 3中89.5% vs 55.0% ；STEP 4中89.8% vs 70.4%），HbA1c 、空腹血糖（FPG）和胰岛素抵抗指数（HOMA-IR）下降幅度更大。同时，司美格鲁肽组体重降低幅度也更大（STEP 1中下降13.7% vs 2.4%；STEP 3中下降15.5% vs 6.4%；STEP 4中下降16.5% vs 5.2%）。这些数据表明，司美格鲁肽有助于降低心血管疾病风险，为心血管健康带来积极影响。总结：司美格鲁肽的双重价值与临床定位从SELECT研究证实司美格鲁肽能带来硬终点获益，到STEP HFpEF研究显示其对心衰症状的改善效果，再到STEP系列研究在不同人群中展现出的普适性，司美格鲁肽展现出三大核心优势：在机制上，它通过中枢食欲抑制实现减重，同时利用外周作用改善内皮功能、减少炎症并调节心肌能量代谢，达成“减重-护心”的协同效应；在适用人群方面，其研究覆盖了非糖尿病CVD患者、HFpEF（伴或不伴T2DM）患者以及东亚和中国人群等，构建了完整的证据链；在长期效果和安全性上，司美格鲁肽不仅能使患者短期显著减重，还能长期维持体重并持续降低心血管风险，安全性与GLP-1RA类一致，胃肠道事件多为一过性。这些研究共同表明，司美格鲁肽不仅是肥胖管理的强效药物，更是心血管疾病的一级/二级预防工具，为临床提供了 “减重护心” 的双重选择。随着更多真实世界数据的积累，其在肥胖相关心血管疾病中的应用前景将更为广阔。参考文献（上下滑动可查看）1.Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. 2.Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084.3.Kosiborod MN, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 Apr 18;390(15):1394-1407.4.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. 5.Davies M, et al. Presented at the European and International Congress on Obesity (ECO) virtual meeting, May 10–13, 2021.6.Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. 7.Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. 8.Kadowaki T, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. 9.Mu Y, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. 10.Perreault L, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct 1;45(10):2396-2405.声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

2025-05-14

·GlobeNewswire-Health Care

Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.

Renowned Neurologist and Epilepsy Advocate Honored for Decades of Innovation in Therapeutics, Research, and Patient Care BOWIE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Internationally acclaimed neurologist and epilepsy researcher Dr. Orrin Devinsky will be honored with the Lifetime Accelerator Award during the Epilepsy Therapies & Diagnostics Development Symposium in Leesburg, Va. on Thursday, May 29, 2025. This award is given in recognition of Dr. Devinsky’s groundbreaking work advancing epilepsy treatment, pioneering therapeutic development, and his unwavering dedication to improving the lives of people with epilepsy. Each year, the Lifetime Accelerator Award is presented to a physician, scientist, industry leader, or other individual who has demonstrated a lifelong commitment to bringing new therapies to people with epilepsy. Lifetime Accelerator Award recipients are chosen by an independent committee of global thought leaders and clinical investigators in epilepsy and seizure therapy discovery and development. Dr. Devinsky has been a trailblazer in the development of new therapies for epilepsy, most notably serving as the Principal Investigator of the pivotal Phase III cannabidiol (CBD) trials for Dravet Syndrome and Lennox-Gastaut Syndrome. Both published in the New England Journal of Medicine, these trials were instrumental in demonstrating the efficacy of CBD in reducing seizures, a milestone that helped change the therapeutic landscape for drug-resistant epilepsies. His research has also centered on high-need areas in the epilepsy community, including therapeutic evolution for developmental and epileptic encephalopathies. His work was pivotal in advancing lorcaserin and fenfluramine He is a recognized leader in epilepsy mortality prevention, having founded and served as Principal Investigator of the North American SUDEP (Sudden Unexplained Death in Epilepsy) Registry. Additionally, he co-developed the QOLIE (Quality of Life in Epilepsy), a standardized and widely adopted tool for assessing the impact of epilepsy beyond seizures. Dr. Devinsky has authored over 700 peer-reviewed journal articles and co-founded the Epilepsy Therapy Project and Epilepsy.com, the largest online platform for epilepsy information and support. He is also the author of Epilepsy: Patient and Family Guide, a widely used resource for families navigating epilepsy care. In addition to his clinical and academic work, Dr. Devinsky founded FACES (Finding A Cure for Epilepsy and Seizures), which has supported numerous early-stage and “n-of-1” studies to bring promising treatments for rare and complex neurological disorders to the forefront. His research has received support from the Epilepsy Foundation, National Institutes of Health, National Science Foundation, Centers for Disease Control, Department of Defense, Simons Foundation and other organizations. He has played a key role in building and leading large-scale initiatives. “I’m deeply honored to receive the Lifetime Accelerator Award,” said Dr. Devinsky. “This recognition reflects the collective efforts of the incredible teams, families, researchers, and patients I’ve had the privilege to work with throughout my career. Advancing care for people with epilepsy has been the mission of my life, and I remain as committed as ever to pushing the boundaries of what’s possible in neurological care.” Dr. Devinsky’s distinguished academic and clinical career spans decades of leadership and innovation. A Yale University graduate (B.S., M.S., magna cum laude), he earned his M.D. from Harvard University (cum laude) before completing prestigious fellowships at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS). He is board-certified in Neurology and Clinical Neurophysiology and has served numerous academic and hospital leadership roles, including Director of the NYU Comprehensive Epilepsy Center since 1989. Throughout his career, Dr. Devinsky has held influential positions in professional societies such as the American Epilepsy Society and American Academy of Neurology, serving on committees, advisory boards, and editorial boards for over three decades. He remains a trusted voice across academia, biotech, and public health. The Lifetime Accelerator Award acknowledges his exceptional impact and enduring legacy in the field of neuroscience and beyond. To watch Dr. Devinsky receive his Lifetime Accelerator Award, register for the livestream of the Foundation’s Shark Tank Competition. About EpilepsyEpilepsy is considered by world experts to be the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. The U.S. Centers for Disease Control & Prevention (CDC) estimates that 3.4 million people in the United States are affected by epilepsy. Epilepsy is the underlying tendency of the brain to produce seizures which are sudden abnormal bursts of electrical energy that disrupt brain functions. About the Epilepsy Foundation of AmericaThe Epilepsy Foundation is a national nonprofit organization dedicated to improving the lives of people affected by epilepsy through education, advocacy, research, and connection. For more than five decades, the Epilepsy Foundation has shone a light on epilepsy to promote awareness and understanding, and to advocate for laws that matter to people with epilepsy, while also funding epilepsy research and supporting epilepsy investigators and specialists in their early careers. In partnership with the CDC, the Epilepsy Foundation has helped to improve access to care for people with epilepsy and trained more than 600,000 people in seizure recognition and first aid. The Epilepsy Foundation continues to focus on serving the epilepsy community through advocacy, education, direct services, and research for new therapies. To learn more visit epilepsy.com or call 1.800.332.1000; in Spanish at 866.748.8008 or laepilepsia.org. Follow us on Facebook, Instagram, Twitter, LinkedIn, TikTok, and YouTube. MEDIA CONTACT: Kaitlyn Gallagher 301.918.3756 kgallagher@efa.org

临床3期

100 项与盐酸绿卡色林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06613	盐酸绿卡色林	A08AA11	DB04871

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Eisai, Inc.	2012-06-27
肥胖	美国	Arena Pharmaceuticals, Inc.	2012-06-27
超重	美国	Arena Pharmaceuticals, Inc.	2012-06-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
Dravet综合征	临床3期	美国	Eisai, Inc.	2020-09-23
Dravet综合征	临床3期	加拿大	Eisai, Inc.	2020-09-23
2型糖尿病	临床3期	美国	Eisai, Inc.	2007-12-01
尼古丁成瘾	临床2期	美国	Arena Pharmaceuticals, Inc.	2014-03-01
药物滥用	临床1期	加拿大	Eisai, Inc.	2008-12-01
发育性癫痫性脑病	临床前	美国	Harmony Biosciences LLC	2024-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03192995 (TLC, CTgov)	临床2期	可卡因相关疾病	22	Cocaine metabolites+lorcaserin (Experimental)	遞獵鹹顧製齋繭艱醖淵(醖築廠膚鹹鬱醖膚餘獵) = 鏇艱齋觸糧顧壓齋積壓構餘鬱鑰遞選淵鹽鬱艱 (遞膚繭壓鏇衊蓋積艱鹹, 27.7) 更多	-	2023-08-14
				Placebo Oral Tablet (Control)	遞獵鹹顧製齋繭艱醖淵(醖築廠膚鹹鬱醖膚餘獵) = 襯窪願鬱網遞觸蓋構窪構餘鬱鑰遞選淵鹽鬱艱 (遞膚繭壓鏇衊蓋積艱鹹, 21.7) 更多
NCT03253926 (CTgov)	临床1/2期	大麻滥用	15	Lorcaserin+Marijuana (Lorcaserin + Marijuana)	獵壓窪鹽鹽夢範選廠鬱(簾遞糧製遞壓範範餘襯) = 簾獵積襯夢鑰範鑰製醖範願淵襯蓋鹹廠選襯鏇 (製獵獵製獵膚蓋遞網襯, 1) 更多	-	2022-07-26
				Placebo+Marijuana (Placebo + Marijuana)	獵壓窪鹽鹽夢範選廠鬱(簾遞糧製遞壓範範餘襯) = 製顧鬱顧窪範顧夢製遞範願淵襯蓋鹹廠選襯鏇 (製獵獵製獵膚蓋遞網襯, 1) 更多
NAASO2021	N/A	-	-	Lorcaserin	網夢膚選繭獵範襯網蓋(願獵襯鹽鹽糧醖膚選鏇): HR = 0.91 (95% CI, 0.76 ~ 1.09)	-	2021-12-06
				Phentermine-topiramate
NCT03353220 (CTgov)	临床4期	体重下降 \| 肥胖	32	placebo+Belviq (Placebo)	鹹膚構構廠艱窪繭構製(構鬱獵膚範餘觸醖糧蓋) = 願願衊鬱鏇遞壓範餘鏇夢遞壓蓋簾壓願構廠構 (遞範蓋製獵繭鬱鑰憲範, 118.7) 更多	-	2021-09-23
				Lorcaserin (Lorcaserin)	鹹膚構構廠艱窪繭構製(構鬱獵膚範餘觸醖糧蓋) = 壓窪範衊選選鏇衊顧餘夢遞壓蓋簾壓願構廠構 (遞範蓋製獵繭鬱鑰憲範, 109.0) 更多
NCT03338296 (CTgov)	临床4期	体重下降 \| 肥胖	278	Placebo	繭鏇積顧憲網憲鬱顧獵(襯鬱餘鹹範齋鹹膚簾網) = 觸鹹選積網積醖遞廠觸觸築蓋糧繭鑰襯鹽窪顧 (網鏇鹽製夢憲鑰繭鑰鹽, 2.317) 更多	-	2021-07-19
NCT03192995 (Pubmed \| PLoS One)	临床2期	-	-	Lorcaserin 20 mg	鏇衊範鬱構鏇遞顧淵艱(觸蓋獵壓遞壓襯齋艱淵) = 襯積構鹹鏇餘願窪膚鹽鏇膚觸積廠觸鏇憲鏇鹽 (襯築餘夢積衊醖夢繭鏇 )	-	2021-07-15
				Placebo	鏇衊範鬱構鏇遞顧淵艱(觸蓋獵壓遞壓襯齋艱淵) = 範鹹鹽膚遞網蓋築鹹觸鏇膚觸積廠觸鏇憲鏇鹽 (襯築餘夢積衊醖夢繭鏇 )
NCT02537873 (Pubmed \| Front Psychiatry) 人工标引	临床1期	可卡因相关疾病	25	Cocaine+Lorcaserin Hydrochloride	鹽艱齋襯遞積獵鏇壓顧(壓鹹襯製醖鹽艱憲鑰蓋) = There were no significant interactions between cocaine and lorcaserin on cardiovascular measures, plasma cocaine, or subjective ratings. 醖淵遞構遞膚鏇壓鑰糧 (築齋齋醖廠顧積鑰齋構 ) 更多	不佳	2021-07-02
				Cocaine+Placebo
NCT02412631 (CTgov)	临床2/3期	尼古丁成瘾 \| 肥胖 \| 体重增加	84	Placebo+Varenicline (Varenicline Plus Placebo)	艱憲願繭廠窪構衊網網(範壓齋範蓋衊遞壓鏇鏇) = 窪膚壓齋選選鑰願鏇選鬱壓襯遞範糧鹽遞網獵 (範網淵窪襯夢願選鑰蓋, 8.38) 更多	-	2021-06-10
				Varenicline+lorcaserin (Varenicline Plus Lorcaserin)	艱憲願繭廠窪構衊網網(範壓齋範蓋衊遞壓鏇鏇) = 鬱夢憲糧艱醖顧夢鹹築鬱壓襯遞範糧鹽遞網獵 (範網淵窪襯夢願選鑰蓋, 2.07) 更多